Recent guidelines recommend that GLP-1 receptor agonists (GLP-1 RA) or SGLT2 inhibitors (SGLT2i) with proven benefits should be used in established atherosclerotic cardiovascular disease (ASCVD) to reduce major adverse cardiovascular events. This evidence concerns the gene SLC5A2 and atherosclerosis.